Navigation Links
Patients Taking VIMOVO(TM) Showed a Decrease in Incidence of NSAID-Associated Ulcers
Date:10/19/2009

PHILADELPHIA, Oct. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and POZEN Inc. (Nasdaq: POZN) today announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology (ACR) 2009 Annual Scientific Meeting in Philadelphia, PA.

The data demonstrated that patients at risk for developing NSAID-associated gastric ulcers taking VIMOVO(TM) (naproxen/esomeprazole magnesium, formerly known as PN 400) experienced significantly fewer endoscopically confirmed gastric ulcers (GU) compared with patients taking enteric-coated (EC) naproxen (500 mg) alone. Data from study PN400-301 showed a 4.1% incidence of GU in patients taking VIMOVO, compared to 23.1% among patients taking EC naproxen (p<0.001). Study PN400-302 showed a 7.1% incidence of GU among patients taking VIMOVO, compared to 24.3% with EC naproxen (p<0.001).

VIMOVO is a fixed-dose combination of enteric-coated naproxen, a non-steroidal anti-inflammatory drug (NSAID) and immediate release esomeprazole, a proton pump inhibitor (PPI), under investigation for the treatment of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in patients who are at risk of developing NSAID-associated gastric ulcers.

"These results provide new information about VIMOVO and the incidence of NSAID-induced endoscopically confirmed gastric ulcers in patients with osteoarthritis," said Marc C. Hochberg, M.D., M.P.H., professor of medicine and head of the Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine in Baltimore, and co-principal investigator for the study. "If approved, VIMOVO will provide arthritis patients at risk for NSAID associat
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ULORIC(R) (febuxostat) Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout
2. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
3. Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences
4. New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
5. Breast Cancer Survivors and Patients Encouraged to Have Medical History Readily Available
6. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
7. Fresenius Medical Care, N.A. Has Selected VitalRemedyMDs VitalProteinRx(TM) As Its Bar of Choice for Protein Replacement in Dialysis Patients
8. Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis
9. Breast-Specific Gamma Imaging Proves Cost-Effective for Pre-Surgical Planning of Patients with Known Cancer Diagnosis
10. Latest Content Release for The T SystemEV EDIS Supports Clinicians in Providing Quality Care for H1N1 Patients
11. Outcomes Registry in Heart Attack Patients to Generate Numerous Studies; Data Quality Ensured Through Velos Clinical Research Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical ... for infectious diseases, announced today the addition of ... key opinion leader in the areas of pneumonia ... Founder and Chief Executive Officer, ... Opal,s extensive experience investigating bacterial toxins and key ...
(Date:11/26/2014)... and LONDON , Nov. ... market intelligence, MarketResearch.com is pleased to announce the distribution ... Consultancy focusing on the active pharmaceutical ingredient (API) market. ... http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s newest ... Forecast to 2020 , IQ4I analysts ...
(Date:11/26/2014)... Nov. 25, 2014  At the American Dental Association,s ... this October, KaVo Kerr Group was honored to be ... attendees the opportunity to see and test the Best ... leaders deliver lectures on the latest developments in dental ... the new DEXIS CariVu Caries Detection Device and Kerr ...
Breaking Medicine Technology:Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
... 23, 2011 /PRNewswire-Asia/ -- Golden Meditech Holdings Limited ... integrated healthcare enterprise, today announced that the Group has accumulated ... Corporation ("CCBC," - CO.US) from the open market between December ... Group now owns 39.5% of the issued share capital of ...
... Four hospitals serving Virginia patients reduced healthcare-acquired infection rates ... in savings of $1.2 million in additional costs to ... plan to existing federal hand washing protocols, these hospitals ... and reduced patient length-of-stay and unnecessary readmissions. ...
Cached Medicine Technology:Golden Meditech to Increase Stake in NYSE-listed Affiliate -- China Cord Blood Corporation to 39.5% 2Virginia Hospitals Reduce Infections 41% 2Virginia Hospitals Reduce Infections 41% 3
(Date:11/28/2014)... November 28, 2014 Novatus, a ... its Release v5.1 which provides customers with greater ... options. , “As we continue to evolve ... provide more functionality and improved performance in response ... CEO for Novatus. “With the enhancements that we ...
(Date:11/28/2014)... 28, 2014 Dr. Andrew Campbell, one ... announced the expansion of Quintessa Aesthetic Center into a ... located at W307 N1497 Golf Road in Suite 200 ... Dr. Campbell, the new Delafield location will offer a ... patients, including: Botox, filler injectables , micro laser ...
(Date:11/28/2014)... Dr. Paul Vitenas, one of the most awarded cosmetic surgeons ... for those in the area that would like to learn more ... will take place on December 11, 2014, from 6:00 p.m. until ... Houston at 4208 Richmond Ave. , “We want to wish ... and celebrate the season with us on December 11, 2014 from ...
(Date:11/28/2014)... Evergreen, Colorado (PRWEB) November 28, 2014 Written ... Jackson , Brook Forest Voices releases the “The Happiest ... audiobook , a compelling account of how and why Project ... of Idaho by his mother Josie and the Reverend Richard ... millionaire by the age of 30, but realized that he ...
(Date:11/28/2014)... Alex Kramer HealthDay Reporter , ... in the kitchen, through cooking classes or at home, may ... a recent review. Cooking programs and classes for children ... to the new research. And, although the review didn,t look ... such programs might help children develop long-lasting healthy habits. ...
Breaking Medicine News(10 mins):Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3
... , , WEDNESDAY, April 22 (HealthDay News) -- Responding to ... Administration said Wednesday that it will now allow 17-year-olds ... a doctor,s prescription. , In 2006, the FDA ... also known as Plan B, to women 18 and ...
... 22 NuVasive, Inc. (Nasdaq: NUVA ), ... minimally disruptive surgical treatments for the spine, announced today ... New Jersey based company focused on clinical approval of ... disc replacement device. This strategic acquisition allows NuVasive the ...
... TMK ) reported today that for the quarter ... (after a charge of $.49 per share for impairment of ... quarter. Net operating income for the quarter was $1.49 ... per share for the year-ago quarter. Reconciliations between net income ...
... of drinking while pregnant, , , WEDNESDAY, April 22 (HealthDay ... and mental problems in babies born to women who ... known that drinking while pregnant can be harmful to ... to children with noticeable deficits, noted Chris Downing, a ...
... AMICAS, Inc. (Nasdaq: AMCS ), a ... solutions, today announced it will report the company,s financial ... after the market closes on Monday, May 11, 2009.(Logo: ... of its financial results, management will host a conference ...
... To Webcast Annual Shareholders MeetingLIONVILLE, Pa., April 22 ... announced today that it will release 2009 first quarter ... 30, 2009, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ...
Cached Medicine News:Health News:FDA Approves 'Plan B' Pill for 17-Year-Olds 2Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 2Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 3Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 4Health News:Torchmark Corporation Reports First Quarter 2009 Results 2Health News:Torchmark Corporation Reports First Quarter 2009 Results 3Health News:Torchmark Corporation Reports First Quarter 2009 Results 4Health News:Torchmark Corporation Reports First Quarter 2009 Results 5Health News:Torchmark Corporation Reports First Quarter 2009 Results 6Health News:Torchmark Corporation Reports First Quarter 2009 Results 7Health News:Torchmark Corporation Reports First Quarter 2009 Results 8Health News:Torchmark Corporation Reports First Quarter 2009 Results 9Health News:Torchmark Corporation Reports First Quarter 2009 Results 10Health News:Torchmark Corporation Reports First Quarter 2009 Results 11Health News:Torchmark Corporation Reports First Quarter 2009 Results 12Health News:AMICAS Schedules First Quarter 2009 Earnings Results Conference Call 2Health News:West to Host 2009 First Quarter Conference Call 2
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
... wide orifice tip, the Finntip Wide is ... and macromolecules like genomic DNA. This tip ... fragmentation. It is excellent for use with ... the inside diameter of the orifice is ...
... designed to optimize the accuracy and precision ... products is widely recognized by customers throughout ... extended over the years and now covers ... tips including filter tips, certified pure tips, ...
... plastic-wrapped racks of 96 tips, Sterilized Diamond- ... autoclave. Sterilized Diamond Tips are irradiated by ... delivered with a certificate of sterilization, specifying ... are certified free of detectable Rnase, Dnase, ...
Medicine Products: